EL7.AI
StocksMedium•17 November 2026•
4 min read

Biogen reports 38% slowing in decline on Alzheimer’s measure with experimental treatment

Key Facts

1Biogen announced the results on November 17, 2026, covering the week 96 readout; the twice-yearly 60 mg regimen recorded the greatest treatment effects.
2Slowing of decline on the CDR-SB measure was 38% at week 96, versus 26% at week 76, with a treatment difference of 1.09 points at week 96.
3Five of six measures showed greater slowing at week 96 than at week 76.
4The analysis of the 60 mg regimen was based on 60 participants and compared with 115 participants originally randomized to placebo in the open-label extension analysis.
5CELIA included 416 participants and did not meet its primary endpoint at week 76.

Biogen announced results on November 17, 2026, from week 96 of the Phase 2 CELIA study, saying the experimental treatment diranersen slowed clinical decline associated with Alzheimer’s across measures of cognition, function and disease progression. The twice-yearly 60 mg regimen recorded the greatest treatment effects at two years, according to the company’s statement. In that regimen group, slowing of decline on the CDR-SB measure was 38% at week 96, equivalent to a treatment difference of 1.09 points. The rate on the same measure was 26% at week 76, during the controlled comparison period. Biogen said slowing was greater at week 96 than at week 76 on five of six measures. The readout covers follow-up extended to two years, while the results remain Phase 2 data for a treatment that has not received regulatory approval.

The reported improvement extended to other measures, with results varying from one measure to another. The treatment effect on ADAS-Cog13 rose from 42% at week 76 to 54% at week 96. On the ADCS-ADL-MCI measure, the effect moved from 0% to 30% between the two time points. The treatment effect also rose from 23% to 38% on ADCOMS, and from 30% to 46% on Modified iADRS. On the MMSE measure, however, the rate fell from 50% at week 76 to 38% at week 96, even though the company said five of the six measures showed greater slowing at two years. These figures present a time-based comparison between the week 76 and week 96 readouts, not a uniform result across all study measures.

The two-year analyses are based on an ongoing open-label extension, rather than a continuation of the original blinded, placebo-controlled comparison. The company compared results for the 60 mg regimen, which included 60 participants, with participants originally randomized to the placebo group, numbering 115. Biogen said some members of the comparison group received one dose or no doses after transitioning to the extension phase. Week 96 results therefore reflect a comparison between participants who continued on the same dose and those who switched from the placebo group. The company said the drug was "generally well tolerated over two years, with no new safety signals observed." This is the company’s description of safety over the stated follow-up period; it said development and evaluation of the treatment will continue.

The global, randomized, double-blind, placebo-controlled CELIA study includes 416 participants with mild cognitive impairment due to Alzheimer’s or mild Alzheimer’s dementia, none of whom had previously received anti-amyloid treatment. The intrathecal dosing regimens included 60 mg every six months, 115 mg every six months and 115 mg every three months. The placebo-controlled treatment period lasted 18 months, and the primary endpoint was change from baseline on the CDR-SB measure at week 76. But CELIA did not meet its primary endpoint, which assessed dose response on that measure, according to the company’s topline results statement. In results from the controlled period at 18 months, slowing of decline on CDR-SB was 26% with the 60 mg dose, while this group did not separate from placebo on the ADCS-ADL-MCI measure of daily function at that time. In data from that period, Biogen also said average cerebrospinal fluid levels of total tau fell 50–65% from baseline across the doses studied, and reductions were observed in PET imaging markers of tau accumulation in the brain regions assessed.

D ir anersen targets MAPT mRNA to reduce production of all forms of tau protein, according to Biogen, and received Fast Track designation from the U.S. Food and Drug Administration in 2025. In May 2026, the company said Phase 2 data supported advancing the treatment into registrational development, despite missing the primary endpoint at week 76. It now says the Phase 2 results support continuing its development and evaluation in a Phase 3 trial designed to confirm efficacy and safety. The treatment remains investigational and has not been approved by any regulatory authority. Diranersen data are scheduled to be presented at the CTAD 2026 conference in Boston, held between November 16 and 19, during a session on November 17 from 4:45 to 5:25 p.m. Eastern time. Phase 3 results, in the company’s description of their role, are intended to confirm the efficacy and safety that the open-label extension data have not established.

Open on chart